Comments on: Authorized Generics Agreements to Increase http://blog.pharmexec.com/2009/07/29/authorised-generics-agreements-to-increase-2/ The Business of Pharmaceuticals Wed, 08 Feb 2012 14:53:10 -0500 hourly 1 By: Adam Fein http://blog.pharmexec.com/2009/07/29/authorised-generics-agreements-to-increase-2/comment-page-1/#comment-38557 Adam Fein Wed, 29 Jul 2009 17:19:44 +0000 http://blog.pharmexec.com/?p=940#comment-38557 Authorized generics appear to be pro-competitive in the short term because prices are lower in the initial 180 days when there are three competitors (brand, AG, and generic first-to-file). The real risk comes from the long-term competitive effect on future ANDA filings. Will generic manufacturers be deterred in the future by the threat (real or implied) that the brand name competitor will reduce the value of the 180-day exclusivity period? See my article for more: http://www.drugchannels.net/2009/06/authorized-generics-money-saver-or-evil.html BTW, interested readers could learn a lot about authorized generics from a recent (free) FTC report on the topic before dropping $5,700 on the Datamonitor report: http://ftc.gov/os/2009/06/P062105authorizedgenericsreport.pdf Adam Authorized generics appear to be pro-competitive in the short term because prices are lower in the initial 180 days when there are three competitors (brand, AG, and generic first-to-file).

The real risk comes from the long-term competitive effect on future ANDA filings. Will generic manufacturers be deterred in the future by the threat (real or implied) that the brand name competitor will reduce the value of the 180-day exclusivity period? See my article for more:
http://www.drugchannels.net/2009/06/authorized-generics-money-saver-or-evil.html

BTW, interested readers could learn a lot about authorized generics from a recent (free) FTC report on the topic before dropping $5,700 on the Datamonitor report:
http://ftc.gov/os/2009/06/P062105authorizedgenericsreport.pdf

Adam

]]>